Patents Examined by Edward J. Webman
-
Patent number: 7316821Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: June 18, 2004Date of Patent: January 8, 2008Assignee: Purdue Pharma, L.P.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 7307043Abstract: An aqueous composition suitable for applying insecticides or acaricides to plant propagation materials comprising water, an insecticidally or acaricidally effective amount of at least one nitroimino- or nitroguanidino-compound in free form or in agrochemically useful salt form and a blend of the following components, by weight: a) 2-10% of a surface-active agent comprising a1) at least one anionic surfactant; b) 4-20% of at least one inorganic solid carrier; and c) 3-25% of at least one antifreeze agent. In one embodiment, the aqueous composition further comprises a fungicidally effective amount of at least one fungicidally active compound. The inventive composition is storage stable, ready-to-apply (RTA), ecologically and toxicologically favorable and has good fungicidal efficacy.Type: GrantFiled: August 17, 2004Date of Patent: December 11, 2007Assignee: Syngenta Crop Protection, Inc.Inventors: Christian Schlatter, Ravi Ramachandran
-
Patent number: 7244418Abstract: A composition for forming an antimicrobial artificial nail, a method for preparing the same, and a method for treating a microbial infection of a nail plate are provided. The composition comprises a binder component; a filler component which polymerizes to form an acrylic matrix subsequent to contact with the binder component; and an antimicrobial agent available for diffusion from the acrylic matrix.Type: GrantFiled: September 17, 2002Date of Patent: July 17, 2007Assignee: Woodward Laboratories, Inc.Inventors: David Dyer, Kenneth B. Gerenraich
-
Patent number: 7229630Abstract: The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.Type: GrantFiled: June 20, 2003Date of Patent: June 12, 2007Assignee: Novalar Pharmaceuticals, Inc.Inventors: Andrew X. Chen, Julius Knowles, Eckard Weber
-
Patent number: 7226615Abstract: Liquid, injectable, aqueous solutions are transformed in situ to an expandable foam-like, space filling, and adherent biomaterial. Preferably, the foam-like biomaterial is the reaction product of a two-part liquid system to achieve the in situ formation thereof. The liquid system is generally comprised of a protein solution and a cross linker solution which may either be premixed and then applied to a site in need of the biomaterial, or simultaneously mixed and delivered through an in-line mixing/dispensing tip directly to the site. In especially preferred embodiments, an expandable foam-like biomaterial includes the reaction product of human or animal-derived protein material and a di- or polyaldehyde in the presence of a bicarbonate and an acidic titrant amounts sufficient to impart a cellular foam structure to the material.Type: GrantFiled: November 7, 2001Date of Patent: June 5, 2007Assignee: CryoLife, Inc.Inventors: K. Ümit Yüksel, Ana T. Bird, Kirby S. Black
-
Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
Patent number: 7201923Abstract: A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished at a low temperature and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liquid content of the liquid encapsulant component provides substantially all or completely all of the liquid plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixture or dough. Removal of liquid plasticizer prior to extrusion is not needed to adjust the viscosity of the mixture for formability.Type: GrantFiled: January 20, 1999Date of Patent: April 10, 2007Assignee: General Mills, Inc.Inventor: Bernhard H. van Lengerich -
Patent number: 7202281Abstract: The present invention relates to a method for reducing adhesions associated with post-operative surgery. The present method comprises administering or affixing a polymeric composition preferably comprising chain extended, coupled or crosslinked polyester/poly(oxyalkylene) ABA triblocks or AB diblocks having favorable EO/LA ratios to a site in the body which has been subjected to trauma, e.g. by surgery, excision or inflammatory disease. In the present invention, the polymeric material provides a barrier to prevent or reduce the extent of adhesions forming.Type: GrantFiled: December 31, 2003Date of Patent: April 10, 2007Assignee: Synthemed, Inc.Inventors: Daniel Cohn, Eli Pines, Anna Hotovely
-
Patent number: 7192599Abstract: The present invention relates to cosmetic and pharmaceutical oil-in-water emulsions which have a mattifying effect when applied to the skin. The invention comprises a hydrophilic, non-organically modified magnesium aluminum silicate or a bentonite clay and a polyol in the water phase; and a volatile, skin-compatible, lipophilic solvent and a high melting point lipophilic plasticizer in the oil phase. A preferred surfactant system to stabilize the emulsion includes non-toxic metal alkyl sulfates and/or sucrose esters.Type: GrantFiled: June 3, 2002Date of Patent: March 20, 2007Assignee: MMP, Inc.Inventors: Michel F. Mercier, Paul Thau, John A. Chase
-
Patent number: 7192604Abstract: An implantable biodegradable device is disclosed containing a fibrous matrix, the fibrous matrix being constructed from fibers A and fibers B, wherein fibers A biodegrade faster than fibers B, fibers A and fibers B are present in relative amounts and are organized such that the fibrous matrix is provided with properties useful in repair and/or regeneration of mammalian tissue.Type: GrantFiled: December 7, 2001Date of Patent: March 20, 2007Assignee: Ethicon, Inc.Inventors: Kelly R. Brown, Iksoo Chun, Joseph J. Hammer, Victor F. Janas, Jennifer Mandanas, Mora C Melican, Alireza Rezania, Mark C. Zimmerman
-
Patent number: 7189414Abstract: The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation, wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and/or the agent which inhibits intestinal drug degradation.Type: GrantFiled: July 31, 2003Date of Patent: March 13, 2007Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Abraham Rubinstein, Michael Friedman, Muhammad Baluom, Boaz Tirosh
-
Patent number: 7189413Abstract: Degradable blend of polycaprolactone and crystallization modifier especially suitable for use in the controlled release of biologically active proteinsType: GrantFiled: February 14, 2002Date of Patent: March 13, 2007Assignee: Genzyme CorporationInventors: Pericles Calias, Robert J. Miller, James R. Olson
-
Patent number: 7172770Abstract: The present invention encompasses novel mesoporous compositions comprising vitamin E and alumina, and methods for their synthesis. The mesoporous compositions of the present invention have applications as drug-delivery vehicles.Type: GrantFiled: February 19, 2002Date of Patent: February 6, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Ying Ma, Kenneth J. Balkus, Jr.
-
Patent number: 7169411Abstract: A composition for facilitating delivery of biological agents, comprising a therapeutic or diagnostic agent and a supramolecular complex, the latter comprising (i) a block copolymer, having at least one nonionic, water soluble segment and at least one polyionic segment, and (ii) at least one charged surfactant having hydrophobic groups. The charge of the surfactant is opposite to the charge of the polyionic segment of the block copolymer. The constituents of the supramolecular complex are bound by interaction between the opposite charges thereof and between surfactant hydrophobic groups. The therapeutic or diagnostic agent may be an ionic substance, in which case the ionic substance has a net charge opposite to that of the block copolymer, the net charge being no more than 10.Type: GrantFiled: June 11, 1998Date of Patent: January 30, 2007Assignees: The University of Nebraska Board of Regents, McGill University, The Moscow State UniversityInventors: Alexander V. Kabanov, Adi Eisenberg, Victor A. Kabanov
-
Patent number: 7163699Abstract: The invention concerns a progestin co-micronized with a surfactant and a pharmaceutical composition comprising said gestagenic. The invention also concerns methods for preparing same.Type: GrantFiled: February 27, 2002Date of Patent: January 16, 2007Assignee: Laboratories Besins InternationalInventor: Jerome Besse
-
Patent number: 7160557Abstract: A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as compared to release from the polymeric matrix not incorporating the hydrophobic compound into the polymeric material. In contrast to methods in which a surfactant or lipid is added as an excipient, the hydrophobic compound is actually integrated into the polymeric matrix, thereby modifying the diffusion of water into the microparticle and diffusion of solubilized drug out of the matrix. The integrated hydrophobic compound also prolongs degradation of hydrolytically unstable polymers forming the matrix, further delaying release of encapsulated drug.Type: GrantFiled: December 6, 2000Date of Patent: January 9, 2007Assignee: Acusphere, Inc.Inventors: Howard Bernstein, Donald Chickering, Sarwat Khattak, Julie Straub
-
Patent number: 7153522Abstract: Percutaneous sorbefacients comprising hexylene glycol and 1-menthol, more particularly, percutaneous sorbefacients for female hormones or derivatives thereof; and preparations for percutaneous absorption which comprise a styrene/isoprene/styrene block copolymer and/or polyisobutylene, a softener and a tackifier as the base components, hormones, in particular, follicle hormone and/or luteal hormone as the drug component and hexylene glycol and 1-menthol as a sorbefacient.Type: GrantFiled: October 14, 1999Date of Patent: December 26, 2006Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasuhiro Ikeura, Masayoshi Maki
-
Patent number: 7153518Abstract: Disclosed herein are novel injectable, biocompatible compositions, preferably, comprising a combination of particulate, processed tissue and a carrier. Specifically disclosed are compositions comprising acellular, pulverized dermis combined with at least one glycosaminoglycan and/or gelatin. The subject compositions provide for improved retention of the composition at the site of implantation. Also disclosed are medical applications using the disclosed compositions, such as cosmetic enhancement or filling in of voids due to abnormalities, injuries, surgery, or aging. In addition, kits comprising at least one container of a freeze-dried, particulate tissue and at least one container of a glycosaminoglycan, or crude platelet extract and used thereof as a wound treatment/dressing, are disclosed.Type: GrantFiled: August 27, 2002Date of Patent: December 26, 2006Assignee: Regeneration Technologies, Inc.Inventors: John F. Wironen, Chris Seid, Rebecca Jaw, Thien Doan, Gregg Ritter, Russell S. Donda
-
Patent number: 7150881Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: GrantFiled: June 26, 1997Date of Patent: December 19, 2006Assignee: Mylan Technologies, Inc.Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Patent number: 7138133Abstract: The present invention is an orally administered liquid pharmaceutical composition that demonstrates excellent physical stability while delivering concentrated levels of the pharmaceutical active(s). Specifically, these compositions for extended periods do not allow the active to precipitate or settle out of solution. Among the advantages of this invention is that the compositions do not require agitation/shaking prior to use as a method to re-suspend or dissolve active drug material to insure even and consistent dosing.Type: GrantFiled: October 10, 2001Date of Patent: November 21, 2006Assignee: The Procter & Gamble CompanyInventors: Douglas Joseph Dobrozsi, Jerry William Hayes, II, Francis Joseph David Bealin-Kelly, Jayant Eknath Khanolkar, Benoit Maurice Mullet, Shane Michael DE LA Harpe, Brian James Robbins
-
Patent number: 7138106Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: GrantFiled: June 5, 2002Date of Patent: November 21, 2006Assignee: Mirco Therapeutics, Inc.Inventors: Scott Evans, Richard J. Greff, James I. Wright